Centre for Peri-operative Medicine and Critical Care Research, Imperial College Healthcare NHS Trust, London, United Kingdom.
PLoS One. 2011 Apr 25;6(4):e18120. doi: 10.1371/journal.pone.0018120.
Statins are drugs that are used to lower plasma cholesterol levels. Recently, contradictory claims have been made about possible additional effects of statins on progression of a variety of inflammatory disorders, including infections. We therefore examined the clinical course of patients admitted to hospital with 2009 pandemic influenza A(H1N1), who were or weren't taking statins at time of admission.
A retrospective case-control study was performed using the United Kingdom Influenza Clinical Information Network (FLU-CIN) database, containing detailed information on 1,520 patients admitted to participating hospitals with confirmed 2009 pandemic influenza A(H1N1) infection between April 2009 and January 2010. We confined our analysis to those aged over 34 years. Univariate analysis was used to calculate unadjusted odds ratios (OR) and 95 percent confidence intervals (95%CI) for factors affecting progression to severe outcome (high dependency or intensive care unit level support) or death (cases); two multivariable logistic regression models were then established for age and sex, and for age, sex, obesity and "indication for statin" (e.g., heart disease or hypercholesterolaemia).
We found no statistically significant association between pre-admission statin use and severity of outcome after adjustment for age and sex [adjusted OR: 0.81 (95% CI: 0.46-1.38); n = 571]. After adjustment for age, sex, obesity and indication for statin, the association between pre-admission statin use and severe outcome was not statistically significant; point estimates are compatible with a small but clinically significant protective effect of statin use [adjusted OR: 0.72 (95% CI: 0.38-1.33)].
In this group of patients hospitalized with pandemic influenza, a significant beneficial effect of pre-admission statin use on the in-hospital course of illness was not identified. Although the database from which these observations are derived represents the largest available suitable UK hospital cohort, a larger study would be needed to confirm whether there is any benefit in this setting.
他汀类药物是用于降低血浆胆固醇水平的药物。最近,关于他汀类药物对各种炎症性疾病(包括感染)进展可能产生的额外作用,出现了相互矛盾的说法。因此,我们研究了在医院就诊的 2009 年甲型 H1N1 流感患者的临床病程,这些患者在入院时是否正在服用他汀类药物。
我们使用英国流感临床信息网络(FLU-CIN)数据库进行了回顾性病例对照研究,该数据库包含了 2009 年 4 月至 2010 年 1 月期间在参与医院确诊为 2009 年甲型 H1N1 流感感染的 1520 名患者的详细信息。我们将分析仅限于年龄超过 34 岁的患者。单变量分析用于计算影响严重结局(高依赖或重症监护病房支持)或死亡(病例)进展的因素的未调整优势比(OR)和 95%置信区间(95%CI)。然后,我们建立了两个多变量逻辑回归模型,一个用于年龄和性别,另一个用于年龄、性别、肥胖和“他汀类药物的适应证”(例如心脏病或高胆固醇血症)。
在调整年龄和性别后,我们没有发现入院前使用他汀类药物与结局严重程度之间存在统计学显著关联[调整后的 OR:0.81(95%CI:0.46-1.38);n=571]。在调整年龄、性别、肥胖和他汀类药物适应证后,入院前使用他汀类药物与严重结局之间的关联没有统计学意义;点估计值与他汀类药物使用具有较小但临床显著的保护作用一致[调整后的 OR:0.72(95%CI:0.38-1.33)]。
在这组因大流行性流感住院的患者中,入院前使用他汀类药物对住院期间疾病进程没有显著有益影响。尽管这些观察结果所来自的数据库代表了英国可获得的最大合适医院队列,但需要进行更大的研究来确认在这种情况下是否存在任何益处。